Delineation of the interactions between the chemotherapeutic agent eribulin mesylate (E7389) and human CYP3A4

Cancer Chemotherapy and Pharmacology
Z-Y ZhangY Nancy Wong

Abstract

Eribulin mesylate (E7389), a structurally simplified, synthetic analog of the marine natural product halichondrin B, acts by inhibiting microtubule dynamics via mechanisms distinct from those of other tubulin-targeted agents. Eribulin is currently in Phase III clinical trials for the treatment of metastatic breast cancer. Since drug-induced modulation of cytochrome P450 enzymes, particularly CYP3A4, is a frequent cause of drug-drug interactions, we examined the effects of eribulin on the activity and expression of hepatic and recombinant CYP3A4 (rCYP3A4) in vitro. Identification of the enzyme(s) responsible for eribulin metabolism was based on compound depletion and metabolite formation in reaction mixtures containing subcellular liver fractions or primary human hepatocytes, plus recombinant Phases I and II metabolic enzymes. The role of the enzyme(s) identified was confirmed using enzyme-selective inhibitors and the correlation with prototypic enzyme activity. The effect of eribulin on enzymatic activity was characterized using both microsomal preparations and recombinant enzymes, while the possible modulation of protein expression was evaluated in primary cultures of human hepatocytes. Eribulin was primarily metabolized by CY...Continue Reading

References

Aug 1, 1994·British Journal of Clinical Pharmacology·T AnderssonD J Birkett
Jan 1, 1997·Pharmacology & Therapeutics·L S Kaminsky, Z Y Zhang
Apr 1, 1997·Biopharmaceutics & Drug Disposition·M H CourtD J Greenblatt
Jul 24, 1998·Archives of Biochemistry and Biophysics·V E KostrubskyJ F Sinclair
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Gang LuoLiang-Shang Gan
Jun 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Zhi-Yi ZhangY Nancy Wong
Oct 3, 2002·Journal of the American Chemical Society·Michael J DabrowskiWilliam M Atkins
Mar 19, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Hiroyoshi NakamuraMitsukazu Kitada
Apr 23, 2003·Trends in Pharmacological Sciences·Sean EkinsJ Andrew Williams
Aug 16, 2003·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Aleksandra GaletinJ Brian Houston
Jul 23, 2004·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Mary F PainePaul B Watkins
Oct 16, 2004·Bioorganic & Medicinal Chemistry Letters·Boris M SeletskyMelvin J Yu
Nov 17, 2004·Current Drug Metabolism·Shufeng ZhouAnlong Xu
Jun 25, 2005·Current Drug Metabolism·Zhi-Yi Zhang, Y Nancy Wong
Jan 24, 2006·Biochemical and Biophysical Research Communications·Zhi-Yi ZhangBruce A Littlefield
Feb 4, 2006·The Journal of Membrane Biology·T W Loo, D M Clarke
Feb 10, 2006·The Journal of Biological Chemistry·Emre M Isin, F Peter Guengerich
Mar 25, 2006·Phytotherapy Research : PTR·S HemaIswarya, Mukesh Doble
Jun 24, 2006·Nature Reviews. Cancer·Charity D Scripture, William D Figg
Sep 7, 2006·Proceedings of the National Academy of Sciences of the United States of America·Marika Ekroos, Tove Sjögren

❮ Previous
Next ❯

Citations

Sep 27, 2012·Cancer Chemotherapy and Pharmacology·L A DevrieseJ H M Schellens
Sep 3, 2011·Investigational New Drugs·Toru MukoharaHironobu Minami
Feb 1, 2012·Biologics : Targets & Therapy·Sarika Jain, Tessa Cigler
Jul 21, 2011·Drugs·Caroline M Perry
Aug 12, 2015·Marine Drugs·Umang SwamiSanjay Goel
Jun 15, 2012·Expert Opinion on Drug Safety·Geraldine O'Sullivan CoyneCatherine M Kelly
May 10, 2011·Cancer Treatment Reviews·Javier CortesStefan Glück
Apr 16, 2011·Critical Reviews in Oncology/hematology·Umang SwamiSanjay Goel
Jul 19, 2012·British Journal of Clinical Pharmacology·Lot A DevrieseJan H M Schellens
Nov 18, 2011·Expert Opinion on Pharmacotherapy·Carole GourmelonMario Campone
Feb 7, 2017·Expert Opinion on Investigational Drugs·Umang SwamiSanjay Goel
May 24, 2012·The Annals of Pharmacotherapy·Jessica N Preston, Meghana V Trivedi
Dec 9, 2017·Future Oncology·Ornella GarroneMarco C Merlano
Jan 27, 2019·British Journal of Cancer·T R Jeffry EvansRebecca Kristeleit
Apr 21, 2012·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Ali McBride, Sara K Butler
Nov 2, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Anne-Charlotte DubbelmanJos H Beijnen
Dec 18, 2010·Xenobiotica; the Fate of Foreign Compounds in Biological Systems·Jan-Shiang TaurY Nancy Wong
Nov 5, 2019·European Journal of Drug Metabolism and Pharmacokinetics·Artitaya ThiengsusukKesara Na-Bangchang
Jun 11, 2009·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Antoinette R TanLee S Rosen
Mar 20, 2021·Breast Cancer Research : BCR·Iain R MacphersonCarlo Palmieri

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved